Association between patient characteristics and treatment group

CharacteristicImmunosuppressantN = 141No immunosuppressantN = 41P value
Age in years, mean (SD)60 (15)58 (19)0.371
Male sex, n (%)94 (66.7)25 (61.0)0.576
White race, n (%)135 (95.7)32 (78.0)0.001
Comorbidities present, n (%)79 (56.0)28 (68.3)0.207
Smoking, n (%)74 (52.5)22 (53.7)1.000
NSAID, n (%)76 (53.9)20 (48.8)0.597
Malignancy type, n (%)0.016
 Melanoma62 (44.0)15 (36.6)
 Solid74 (52.5)19 (46.3)
 Hematological5 (3.5)7 (17.1)
Cancer stagea, n (%)1.000
 III13 (9.6)3 (8.8)
 IV122 (90.4)31 (91.2)
Checkpoint inhibitor type, n (%)0.051
 CTLA-459 (41.8)12 (29.3)
 PD-1/L-145 (31.9)22 (53.7)
 Combinationb37 (26.2)7 (17.1)
Diarrhea grade<  0.001
 14 (2.8)20 (48.8)
 243 (30.5)17 (41.5)
 3–494 (66.7)4 (9.8)
Colitis grade<  0.001
 123 (16.3)14 (34.1)
 259 (41.8)27 (65.9)
 3–459 (41.8)0 (0.0)
Endoscopic evaluation0.223
 Flexible sigmoidoscopy33 (23.4)14 (34.1)
 Colonoscopy108 (76.6)27 (65.9)
Distribution of colitis<  0.001
 Terminal ileum involved10 (7.1)1 (2.4)
 Right colon only4 (2.8)1 (2.4)
 Left colon only48 (34.0)9 (22.0)
 Entire colon39 (27.7)3 (7.3)
 Normal40 (28.4)27 (65.9)
IBD like endoscopic patternc0.229
 Crohn’s colitis32 (31.7)7 (50.0)
 Ulcerative colitis69 (68.3)7 (50.0)

Abbreviation: NSAID, non-steroidal antiinflammatory drugs, CTLA-4 cytotoxic T-lymphocyte antigen-4, PD-1/L-1 programmed cell death receptor-1 and ligand 1, SD standard deviation

a American Joint Committee on Cancer (AJCC) Cancer Staging System, 13 patients are missing

b Combination: ipilimumab + nivolumab

c Only 115 patients were included for the IBD like endoscopic pattern evaluation